Physician profile
Daniel Y Cho
NPI 1396124137
$5,848.21
in general payments reported to CMS, 2019-2025
11 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $190 · 2021: $358 · 2022: $2,095 · 2023: $2,535 · 2024: $295 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,145 · Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,145.00 |
| Food and Beverage | $1,060.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,705.00 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $1,003.43 | 2020-2025 | Invega Sustenna, Invega Trinza, Invega |
| Sage Therapeutics, LLC | $240.95 | 2023 | |
| Neurocrine Biosciences, INC. | $213.93 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $198.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.99 | 2025 | Cobenfy |
| Allergan, INC. | $119.36 | 2020 | |
| Abbvie INC. | $85.80 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.94 | 2021-2022 | |
| Alkermes, INC. | $54.20 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $21.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.